Introduction
============

Postoperative acute kidney injury (AKI) accounts for 18--47% of all hospital-acquired AKIs \[[@B1][@B2]\]. Since the introduction of the first consensus definition of AKI (Risk, Injury, Failure, Loss, and End-stage renal disease \[RIFLE\] \[[@B3]\]) in 2004, and the modified version of the classification proposed by the Acute Kidney Injury Network (AKIN) in 2007 \[[@B4]\], AKI has been shown to be associated with prolonged hospital stays \[[@B5][@B6][@B7]\], and increased morbidity and mortality \[[@B5][@B6][@B8][@B9][@B10][@B11][@B12]\] after cardiac \[[@B5][@B8][@B9][@B11]\] and non-cardiac surgery \[[@B6][@B7][@B9][@B10][@B12]\]. While it is widely accepted that AKI worsens outcomes during hospitalization, there is little information on the effects of postoperative AKI on long-term outcomes \[[@B13][@B14]\]. To our knowledge, no study has investigated the effects of AKI on the long-term outcome of patients who have undergone major abdominal surgery.

Recently, the relationship between AKI and long-term decline in renal function has attracted attention. Although AKI has long been considered a benign, reversible process, researchers have demonstrated that the risks of progression to chronic kidney disease (CKD) and end-stage renal disease (ESRD) may increase, even if renal function recovers completely after AKI in non-surgical settings \[[@B15]\]. It is not clear whether postoperative AKI in non-cardiac and non-transplantation settings worsens renal function in the long term after hospital discharge.

Liver resection is major abdominal surgery and is rarely associated with massive bleeding \[[@B16]\]. If the hypovolemia due to excessive blood loss continues and the reduction in oxygen delivery remains uncorrected, the renal medulla may be susceptible to ischemic acute tubular necrosis \[[@B17]\]; consequently, these patients may experience AKI. This study investigated the effects of AKI within 72 hours after liver resection for hepatocellular carcinoma (HCC) on the long-term outcomes (within 3 years after discharge).

Materials and Methods
=====================

The study was approved by the Clinical Research Ethics Board (No. 1683, January 20, 2014), and the need for informed consent was waived. This report is based on our single-center historical cohort study of patients who underwent liver resection and adheres to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines \[[@B18]\].

Patient inclusion and data collection
-------------------------------------

We conducted a historical cohort study of patients who underwent liver resection for HCC with sevoflurane between January 2004 and October 2011, survived the hospital stay, and were followed for at least 3 years or died within 3 years after hospital discharge. Part of a database comprising 642 patients who underwent liver resection at our hospital was used to obtain data for this study. A previous study \[[@B19]\] based on the same database showed that postoperative AKI was associated with longer hospital stays and higher mortality rates during hospitalization. This database included patient, surgical, anesthetic, and laboratory data, manually abstracted from the patients\' electronic charts. The collected data included age, sex, height, body weight, body mass index, American Society of Anesthesiologists physical status, and history of hypertension, ischemic heart disease, atrial fibrillation, cerebrovascular disease, diabetes mellitus, hyperlipidemia, chronic obstructive pulmonary disease, liver cirrhosis, and peripheral vascular disease. Preoperative use of the following medications was recorded: non-steroidal antiinflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins, steroids, or diuretics. The following surgical and anesthetic factors were recorded: surgical procedure, emergency or elective surgery, thoracic epidural anesthesia, maintenance anesthetic agent, duration of anesthesia and surgery, volume and type of intraoperative fluids administered (crystalloid or colloid), and lowest systolic blood pressure (SBP) during anesthesia. Blood loss was calculated from the increase in weight of the surgical gauze used, the volume of blood and saline suctioned, and the volume of saline used in the surgical field. Major liver resection was defined as a resection of at least three Couinaud liver segments. The colloid solution used during the study period consisted of 6% hydroxyethyl starch (HES) 70/0.5 (Hespander®, Fresenius Kabi Japan, Tokyo, Japan) and 5% albumin. Intraoperative transfusions of red blood cells, fresh frozen plasma, and platelets were recorded. One unit of each blood component was derived from 200 ml of whole blood. Laboratory values obtained from the electronic charts included hemoglobin, serum creatinine concentration (sCr), albumin, total bilirubin, transaminase enzymes, and 15-minute indocyanine green retention rate (ICG-R15).

In addition to the data used in our previous study \[[@B19]\], sCr data after hospital discharge were collected for 3 years or until the patients died. Cancer stage data was collected according to the tumor, node, metastasis (TNM) staging of the American Joint Committee on Cancer/Union Internationale contre le Cancer. The glomerular filtration rate (GFR) was estimated using the formula developed for Japanese adults and adjusted for each 1.73 m^2^ of body surface area: estimated GFR (eGFR) (ml/min/1.73 m^2^) = 194 × sCr (mg/dl)^(−1.094)^ × Age (yr)^(−0.287)^ × 0.739 (if female) \[[@B20]\].

Definitions and outcomes
------------------------

This study investigated the effects of AKI within 72 hours after surgery on long-term outcomes after hospital discharge. AKI was identified based on the AKIN creatinine criteria \[[@B4]\] and defined as an abrupt (within 48 hours) absolute sCr increase of ≥ 0.3 mg/dl, or a percentage sCr increase of ≥ 50% (1.5-fold from baseline) ([Table 1](#T1){ref-type="table"}). Urine output data were not used for diagnosis, as these data were inconsistently charted depending on the site of postoperative recovery.

Outcome variables included mortality, renal dysfunction (eGFR of 45 and 60 ml/min/1.73 m^2^), a composite outcome of mortality or eGFR ≤ 60 ml/min/1.73 m^2^, and a composite outcome of mortality or eGFR ≤ 45 ml/min/1.73 m^2^. The stages of CKD are usually based on measured or estimated GFR thresholds of 90, 60, 45, 30, and 15 ml/min/1.73 m^2^ \[[@B21]\]. We assumed that an eGFR of 60 and 45 ml/min/1.73 m^2^ represented mild and moderate CKD, respectively. We assessed whether each aforementioned outcome occurred in each patient at 1, 2, and 3 years after discharge.

As one purpose of this study was to determine whether postoperative AKI was a risk factor for mortality within 3 years after discharge, our sample size was selected to help ensure stability around the point estimates in our final multivariate model. To avoid overfitting our final outcome model, no less than eight outcome events would be required per covariate of interest. Therefore, to fit a model with eight covariates at maximum, we would require 64 outcome events. Based on an estimated 50% of patients being missing over the 3 years after discharge, an estimated 70% of patients who underwent surgery for HCC, and an estimated 40% mortality rate in the 3 years after discharge (determined by a chart review of 100 patients after liver resection), we calculated that we would need approximately 460 patients. We assumed that we had sufficient patients for a multivariate analysis because we already had 642 patients in our database \[[@B19]\].

Statistical analysis
--------------------

The null hypothesis for this study was that there would be no difference in long-term outcomes (mortality, renal dysfunction \[eGFR of 45 and 60 ml/min/1.73 m^2^\], composite outcome of mortality or eGFR ≤ 60 ml/min/1.73 m^2^ and composite outcome of mortality or eGFR ≤ 45 ml/min/1.73 m^2^) between AKI and non-AKI patients. We decided to include the composite outcomes as outcome variables because some patients died at home before being identified as having a low eGFR. Demographic data, comorbidities, preoperative medications, and anesthesia and surgical data were compared between the AKI and non-AKI patients using the entire cohort. The aforementioned outcome variables were compared between the AKI and non-AKI patients at 1, 2, and 3 years after discharge.

Continuous variables were summarized as the median (25th and 75th percentiles) or the mean ± SD. Categorical variables were summarized as frequency (percentage). Normally and non-normally distributed continuous data were analyzed using Student\'s two-sample t-test and the Wilcoxon rank-sum test, respectively. Categorical data were analyzed using Fisher\'s exact test.

Multivariate Cox proportional hazards regression was used to model the relationship between clinical outcomes, including mortality within 3 years after discharge, and perioperative risk factors. The following factors were selected *a priori* based on their potential association with mortality: age, pre-existing renal failure (preoperative eGFR), pre-existing liver failure (preoperative ICG-R15), major resection, intraoperative red blood cell transfusion (number of units), postoperative AKI, and cancer stage. Since only a few patients were TNM stage IV, stages III and IV were combined for the multivariate analysis. To avoid multicollinearity, we did not simultaneously include two or more predictor variables that were highly correlated (r \> 0.8) in the multivariate analysis model.

All tests were two-sided, and we considered a P value \< 0.05 to be statistically significant. The statistical analyses were performed using STATA software (ver. 13; StataCorp., College Station, TX, USA).

Results
=======

In total, this study identified 695 patients who underwent liver resection between January 2004 and October 2011. After excluding 53 patients in our previous study \[[@B19]\], a further 414 patients were excluded for the reasons shown in [Fig. 1](#F1){ref-type="fig"}, leaving 228 patients for the final analysis. AKI based on the AKIN criteria occurred in 27 patients (11.8%) within the first 72 hours, with all patients being classified as either AKIN stage 1 (n = 22) or 2 (n = 5). No patients classified as AKIN stage 3 were included in the final analysis.

Patients who developed AKI had significantly lower preoperative hemoglobin concentrations, higher sCr levels, lower eGFR, and lower serum albumin concentrations. AKI patients were more likely than non-AKI patients to have peripheral vascular disease. The lowest SBP during anesthesia was significantly lower in AKI patients than in non-AKI patients ([Table 2](#T2){ref-type="table"}).

Although the estimated blood loss was significantly greater in AKI patients than in non-AKI patients, there were no significant differences in the amount of crystalloid administered or percentage of patients who received HES intraoperatively. The percentage of patients who received transfusions of red blood cells, fresh frozen plasma, and platelets was significantly higher in the AKI group than in the non-AKI group. The percentage of patients who underwent major liver resection did not differ significantly between the AKI and non-AKI patients. The durations of surgery and anesthesia did not differ significantly between the AKI and non-AKI patients ([Table 2](#T2){ref-type="table"}).

Although the percentages of patients who reached the threshold eGFR of 45 ml/min/1.73 m^2^ and the composite outcome of mortality or eGFR of 45 ml/min/1.73 m^2^, within 3 years of hospital discharge in the AKI group, were significantly higher than those in the non-AKI group, there were no significant group differences in the percentages of patients who died or reached the composite outcome of mortality or eGFR of 60 ml/min/1.73 m^2^ within 3 years. A Cox proportional hazard regression analysis revealed that postoperative AKI was associated with the composite outcome of mortality or an eGFR of 45 ml/min/1.73 m^2^ ([Table 3C](#T3){ref-type="table"}), but not with mortality ([Table 3A](#T3){ref-type="table"}) or the composite outcome of mortality or an eGFR of 60 ml/min/1.73 m^2^ ([Table 3B](#T3){ref-type="table"}). Higher TNM staging was independently associated with both mortality ([Table 3A](#T3){ref-type="table"}) and the composite outcome of mortality or renal dysfunction ([Tables 3B and 3C](#T3){ref-type="table"}).

Discussion
==========

We assessed the effects of AKI after liver resection on outcomes within 3 years after discharge by comparing mortality rates, renal dysfunction, and composite outcome of mortality or renal dysfunction between AKI and non-AKI patients. A multivariate Cox proportional hazard regression analysis showed that postoperative AKI was independently associated with the composite outcome of mortality or moderate renal dysfunction (eGFR of 45 ml/min/1.73 m^2^) within 3 years after discharge, but not with mortality or the composite outcome of mortality or mild renal dysfunction (eGFR of 60 ml/min/1.73 m^2^).

Postoperative AKI is associated with worse short-term outcomes (*e.g.*, during hospitalization), including higher mortality rates in both cardiac \[[@B8][@B11]\] and non-cardiac surgery \[[@B6][@B10][@B12]\]. However, little is known about the effects of postoperative AKI on long-term outcomes and data are available only for patients who underwent cardiac surgery \[[@B9][@B14]\], transplantation \[[@B22]\], or major cardiothoracic surgery \[[@B13]\]. To our knowledge, no study has investigated the impact of postoperative AKI on long-term outcomes in patients who underwent major abdominal surgery.

Apart from the surgical setting, recent studies suggest that AKI is not always reversible and may lead to CKD and ESRD in the long term, even after renal function recovers to the baseline level \[[@B23]\]. For example, using a database of 233,803 patients, Ishani et al. \[[@B24]\] demonstrated that elderly patients with AKI are at greater risk of ESRD, suggesting that AKI episodes accelerate the progression of renal disease. The renal function outcomes in patients who survive AKI may include full recovery, incomplete recovery resulting in CKD, exacerbation of pre-existing CKD accelerating the progression to ESRD, and non-recovery of kidney function leading to CKD \[[@B23]\]. It is not clear whether AKI after non-cardiac surgery accelerates the progression to CKD (*e.g.*, eGFR of 45 ml/min/1.73 m^2^), and we believe this is worth investigating.

Although postoperative AKI was significantly associated with the composite outcome of mortality or moderate renal dysfunction, the mechanisms behind worse long-term outcome after liver resection are not clear. In terms of the effects of postoperative AKI on worse long-term outcomes in cardiac patients, one possibility is that potential renal dysfunction may have been unmasked by hypotension or reduced blood flow to the kidneys during cardiac surgery in patients with a normal sCr \[[@B25]\]. It is generally accepted that sCr is not a sensitive marker of renal dysfunction and is affected by factors such as age, sex, muscle mass, and protein intake \[[@B26]\]. Since the pathogeneses of both coronary heart disease and renal dysfunction are partly related to atherosclerosis, such potential renal dysfunction may be related to more severe heart disease and thereby worse mortality and progression of renal dysfunction. Another possibility is that although increased sCr is reversible in many cases, renal blood flow and clearance can remain impaired for a prolonged period after an AKI episode. Researchers have demonstrated that ongoing progressive damage after AKI results in a decrease in perpendicular capillary density \[[@B27]\].

The lack of a significant association between AKI after liver resection and mortality ([Table 3A](#T3){ref-type="table"}) may be explained in part by the malignant nature of the disease. Some patients likely died from their malignancy before postoperative AKI had any effects on renal function. We postulate that malignancy was a more important contributor to mortality than was postoperative AKI.

Since cancer stage was independently associated with mortality in this study, the severity and extent of the malignant diseases may have been related to the worse outcomes. Although AKI may lead to CKD or ESRD, as mentioned previously \[[@B23]\], this assumption may not necessarily apply to patients with malignant diseases.

Several limitations of this study need to be addressed. First, as with all observational research, our results may be explained by residual or unmeasured confounders. Generalizability is limited to centers with patient and surgical profiles similar to our own. Second, approximately 64% of the patients were excluded from the study, which may have caused potential bias in the patient population included in the final analysis. Lastly, the AKI observed in this study was mostly mild, which may explain why effects of AKI on long-term outcome were not apparent.

In conclusion, postoperative AKI seems to have a significant relationship with the composite outcome of mortality or moderate renal dysfunction within 3 years. These findings suggest that even after patients are discharged from the hospital, renal function may require long-term follow-up in patients who suffered AKI after liver resection. Further studies may be required to clarify the relationships between postoperative AKI and worse long-term outcomes in patients undergoing major abdominal surgery.

This work was funded by the Department of Anesthesiology, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Japan. Dr. Ishikawa is supported through Grant-in-Aid for Scientific Research ((C) 25462426) from Ministry of Education, Culture, Sports, Science and Technology, Japan. The authors declare no conflict of interest associated with this manuscript.

It was presented the 61th Annual Meeting of the Japanese Society of Anesthesiologists, May 2014, PACIFICO Yokohama, Yokohama, Japan.

![Flow chart outlining the inclusion and exclusion criteria used in this study. Of the 642 patients included in our previous study, 414 were excluded, leaving 228 patients in the final analysis.](kjae-70-527-g001){#F1}

###### AKIN Creatinine Criteria for the Diagnosis of AKI

![](kjae-70-527-i001)

  ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Stage 1                                                                                                                                              150--200% increase in sCr or increase ≥ 0.3 mg/dl from baseline.
  Stage 2                                                                                                                                              200--300% increase in sCr.
  Stage 3                                                                                                                                              \> 300% increase in sCr from baseline or sCr ≥ 4.0 mg/dl with an acute rise of ≥ 0.5 mg/dl.
  Patients who receive RRT are considered to have met the criteria for stage 3 irrespective of the stage that they are in at the time RRT commenced.   
  ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------

AKIN: Acute Kidney Injury Network, AKI: acute kidney injury, sCr: serum creatinine concentration, RRT: renal replacement therapy.

###### Preoperative Patient Characteristics and Intraoperative Variables by AKI Status
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                                 All patients (n = 228)   AKI patients (n = 27)   Non-AKI patients (n = 201)   P value
  ------------------------------ ------------------------ ----------------------- ---------------------------- ----------
  Age (yr)                       67.4 ± 8.9               70.0 ± 8.1              67.0 ± 8.9                   0.097
  Female                         57 (25)                  5 (19)                  52 (26)                      0.485
  Height (cm)                    161.5 ± 9.1              162.8 ± 8.6             161.3 ± 9.1                  0.435
  Body weight (kg)               62.5 ± 12.0              62.8 ± 13.1             62.5 ± 11.9                  0.909
  BMI (kg/m^2^)                  23.9 ± 3.5               23.5 ± 3.7              23.9 ± 3.5                   0.567
  ASA                                                                                                          0.775
   1                             3 (1)                    0 (0)                   3 (1)                        
   2                             196 (86)                 23 (85)                 173 (86)                     
   3                             29 (13)                  4 (15)                  25 (12)                      
   4                             0 (0)                    0 (0)                   0 (0)                        
   5                             0 (0)                    0 (0)                   0 (0)                        
  TNM staging                                                                                                  0.506
   I                             105 (46)                 11 (41)                 94 (47)                      
   II                            84 (37)                  9 (33)                  75 (37)                      
   IIIA or IIIB or IIIC          37 (16)                  7 (26)                  30 (15)                      
   IVA or IVB                    2 (1)                    0 (0)                   2 (1)                        
  Baseline laboratory values                                                                                   
   Hemoglobin (g/dl)             13.0 ± 1.8               12.2 ± 2.1              13.1 ± 1.8                   0.021
   Creatinine (mg/dl)            0.8 ± 0.3                1.0 ± 0.4               0.8 ± 0.2                    \< 0.001
   eGFR (ml/min/1.73 m^2^)       73.6 ± 19.7              64.3 ± 23.1             74.8 ± 18.9                  \< 0.001
   Albumin (g/dl)                3.9 ± 0.5                3.8 ± 0.5               4.0 ± 0.5                    0.044
   Total bilirubin (mg/dl)       0.9 ± 0.4                0.8 ± 0.4               0.9 ± 0.4                    0.610
   GOT (IU/L)                    42 (29--63)              51 (30--63)             41 (29--62)                  0.392
   GPT (IU/L)                    37 (25--58)              35 (25--59)             38 (25--57)                  0.976
   Platelet count (/μl)          15.6 ± 7.0               15.0 ± 9.8              15.7 ± 6.5                   0.664
   ICG-R15 min (%)               19.1 ± 11.3              19.5 ± 10.9             19.0 ± 11.4                  0.818
  Comorbidities                                                                                                
   Hypertension                  126 (55)                 19 (70)                 107 (53)                     0.103
   Ischemic heart disease        18 (8)                   2 (7)                   16 (8)                       1.000
   Atrial fibrillation           11 (5)                   1 (4)                   10 (5)                       1.000
   Cerebrovascular disease       17 (7)                   2 (7)                   15 (7)                       1.000
   Diabetes mellitus                                                                                           0.460
    No diabetes                  169 (74)                 18 (67)                 151 (75)                     
    Oral medication              28 (12)                  5 (19)                  23 (11)                      
    Insulin therapy              31 (14)                  4 (15)                  27 (13)                      
   Hyperlipidemia                17 (7)                   2 (7)                   15 (7)                       1.000
   COPD                          26 (11)                  4 (15)                  22 (11)                      0.523
   Liver cirrhosis               44 (19)                  9 (33)                  35 (17)                      0.067
   Peripheral vascular disease   6 (3)                    3 (11)                  3 (1)                        0.023
  Preoperative medications                                                                                     
   NSAIDs                        6 (3)                    0 (0)                   6 (3)                        1.000
   ACE inhibitors                21 (9)                   1 (4)                   20 (10)                      0.482
   ARB                           45 (20)                  7 (26)                  38 (19)                      0.439
   Statin                        8 (4)                    2 (7)                   6 (3)                        0.242
   Diuretics                     23 (10)                  3 (11)                  20 (10)                      0.741
  Intraoperative variables                                                                                     
   Adjuvant epidural             188 (82)                 19 (70)                 169 (84)                     0.103
   Lowest mean SBP (mmHg)        76.2 ± 11.1              72.1 ± 15.1             76.8 ± 10.3                  0.039
   EBL (ml)                      1122 (579--2211)         1864 (1015--3726)       1038 (568--2144)             \< 0.001
  Intraoperative fluids                                                                                        
   Crystalloid (ml)              4195 (2960--5635)        4750 (3650--6620)       4110 (2900--5470)            0.063
   Received HES                  47 (21)                  3 (11)                  44 (22)                      0.309
  Intraoperative transfusions                                                                                  
   Received RBCs                 68 (30)                  14 (52)                 54 (27)                      0.013
   Units of RBCs                 0 (0--2)                 2 (0--6)                0 (0--2)                     \< 0.001
   Received FFP                  72 (32)                  14 (52)                 58 (29)                      0.026
   Received platelets            28 (12)                  9 (33)                  19 (9)                       0.002
  Surgical procedure                                                                                           
   Major resection               53 (23)                  9 (33)                  44 (22)                      0.224
  Duration of surgery (min)      284 ± 93                 298 ± 89                283 ± 93                     0.420
  Duration of anesthesia (min)   349 ± 94                 361 ± 91                347 ± 94                     0.499

Values are mean ± SD, median (interquartile range) or number of patients (%). AKI: acute kidney injury, BMI: body mass index, ASA: American Society of Anesthesiologists, TNM: tumor, node, metastasis, eGFR: estimated glomerular filtration rate, GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvic transaminase, ICG-R15 min: indocyanine green retention at 15 minutes, COPD: chronic obstructive pulmonary disease, NSAIDs: nonsteroidal anti-inflammatory drugs, ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blockers, SBP: systolic blood pressure, EBL: estimated blood loss, HES: hydroxyethyl starch, RBCs: red blood cells, FFP: fresh frozen plasma.

###### Cox Proportional Hazard Regression Analysis
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  Variable                                                                                                                           HR adj   95% CI       P value
  ---------------------------------------------------------------------------------------------------------------------------------- -------- ------------ ----------
  \(A\) Factors That Are Related to Mortality within 3 Years after Hospital Discharge                                                                      
   Age in years (per 10 years)                                                                                                       1.00     0.73--1.37   0.990
   Preoperative eGFR (per 10 ml/min/1.73 m^2^)                                                                                       0.95     0.84--1.08   0.427
   Preoperative ICG-R15 min, % (SD)                                                                                                  1.01     0.99--1.03   0.190
   Major resection^\*^                                                                                                               1.30     0.70--2.43   0.407
   Red blood cell transfusion (per unit)^†^                                                                                          1.06     1.02--1.10   0.003
   Postoperative AKI                                                                                                                 0.87     0.42--1.78   0.699
   TNM staging                                                                                                                                             
    I (reference)                                                                                                                    1                     
    II                                                                                                                               1.59     0.86--2.96   0.141
    III or IV                                                                                                                        4.07     1.98--8.37   \< 0.001
  \(B\) Factors Related to the Composite Outcome of Mortality or eGFR ≤ 60 ml/min/1.73 m^2^within 3 Years after Hospital Discharge                         
   Age in years (per 10 years)                                                                                                       1.20     0.97--1.50   0.098
   Preoperative eGFR (per 10 ml/min/1.73 m^2^)                                                                                       0.70     0.64--0.77   \< 0.001
   Preoperative ICG-R15 min, % (SD)                                                                                                  1.01     1.00--1.03   0.040
   Major resection^\*^                                                                                                               0.85     0.53--1.35   0.483
   Red blood cell transfusion (per unit)^†^                                                                                          1.01     0.97--1.04   0.684
   Postoperative AKI                                                                                                                 1.26     0.78--2.03   0.347
   TNM staging                                                                                                                                             
    I (reference)                                                                                                                    1                     
    II                                                                                                                               1.27     0.88--1.81   0.198
    III or IV                                                                                                                        2.01     1.20--3.38   0.008
  \(C\) Factors Related to the Composite Outcome of Mortality or eGFR ≤ 45 ml/min/1.73 m^2^within 3 Years after Hospital Discharge                         
   Age in years (per 10 years)                                                                                                       1.35     1.03--1.77   0.028
   Preoperative eGFR (per 10 ml/min/1.73 m^2^)                                                                                       0.75     0.67--0.83   \< 0.001
   Preoperative ICG-R15 min, % (SD)                                                                                                  1.01     0.99--1.02   0.517
   Major resection^\*^                                                                                                               1.14     0.70--1.87   0.604
   Red blood cell transfusion (per unit)^†^                                                                                          1.03     1.00--1.07   0.088
   Postoperative AKI                                                                                                                 1.76     1.05--2.96   0.033
   TNM staging                                                                                                                                             
    I (reference)                                                                                                                    1                     
    II                                                                                                                               1.49     0.95--2.35   0.084
    III or IV                                                                                                                        2.69     1.55--4.67   \< 0.001

HR adj: hazard ratio adjusted, eGFR: estimated glomerular filtration rate, ICG-R15 min: 15-minute indocyanine green retention rate, AKI: acute kidney injury, TNM: tumor, node, metastasis. ^\*^Defined as a resection of at least three Couinaud liver segments. ^†^One unit of each blood component was derived from 200 ml of whole blood.
